| Multiple Myeloma
Kyprolis vs Tecvayli
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Kyprolis vs Tecvayli with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecvayli has a higher rate of injection site reactions vs Kyprolis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecvayli but not Kyprolis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kyprolis
Tecvayli
At A Glance
IV infusion
Once or twice weekly
Proteasome inhibitor
SC injection
Weekly to every 4 weeks
BCMA-directed CD3 T-cell engager
Indications
- Multiple Myeloma
- Multiple Myeloma
Dosing
Multiple Myeloma 20/70 mg/m2 IV once weekly as a 30-minute infusion on Days 1, 8, and 15 of each 28-day cycle (in combination with dexamethasone, daratumumab plus dexamethasone, or daratumumab and hyaluronidase-fihj plus dexamethasone); start at 20 mg/m2 on Cycle 1, Day 1, escalate to 70 mg/m2 on Cycle 1, Day 8 if tolerated.
Multiple Myeloma 20/56 mg/m2 IV twice weekly as a 30-minute infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (as monotherapy or in combination with dexamethasone, daratumumab plus dexamethasone, daratumumab and hyaluronidase-fihj plus dexamethasone, or isatuximab plus dexamethasone); start at 20 mg/m2 on Cycle 1, Days 1 and 2, escalate to 56 mg/m2 on Cycle 1, Day 8 if tolerated.
Multiple Myeloma 20/27 mg/m2 IV twice weekly as a 10-minute infusion on Days 1, 2, 8, 9, 15, and 16 (Cycles 1-12) or Days 1, 2, 15, and 16 (Cycle 13+) of each 28-day cycle (as monotherapy or in combination with lenalidomide and dexamethasone); start at 20 mg/m2 on Cycle 1, Days 1 and 2, escalate to 27 mg/m2 on Cycle 1, Day 8 if tolerated.
Multiple Myeloma (combination with daratumumab and hyaluronidase-fihj) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 3), then 1.5 mg/kg once weekly (weeks 2-8), 3 mg/kg every 2 weeks (weeks 9-24), and 3 mg/kg every 4 weeks (week 25 onward); administer until disease progression or unacceptable toxicity.
Multiple Myeloma (monotherapy) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 4), then 1.5 mg/kg once weekly; may reduce to 1.5 mg/kg every 2 weeks for patients with complete response or better maintained for at least 6 months.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Anemia, diarrhea, hypertension, fatigue, upper respiratory tract infection, thrombocytopenia, pyrexia, cough, dyspnea, insomnia
Serious Cardiac toxicities, acute renal failure, tumor lysis syndrome, pulmonary toxicity, pulmonary hypertension, venous thrombosis, infusion-related reactions, hemorrhage, hepatic toxicity and failure, thrombotic microangiopathy, posterior reversible encephalopathy syndrome, progressive multifocal leukoencephalopathy
Postmarketing Hemolytic uremic syndrome, hepatitis B virus reactivation, gastrointestinal perforation, pericarditis, cytomegalovirus infection
Most common (>=20%) pyrexia, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, diarrhea, hypogammaglobulinemia, cough, COVID-19, gastroenteritis, weight decreased
Serious pneumonia, cytokine release syndrome, sepsis, pyrexia, COVID-19, febrile neutropenia, gastroenteritis, acute kidney injury, encephalopathy, second primary malignancy
Pharmacology
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome within the 26S proteasome, producing antiproliferative and proapoptotic effects in hematologic and solid tumor cells.
Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds CD3 on T-cells and BCMA on multiple myeloma cells, activating T-cells to release proinflammatory cytokines and lyse myeloma cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kyprolis
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Tecvayli
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Kyprolis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tecvayli
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kyprolis
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tecvayli
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
J&J withMe Savings Program: TecvayliCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KyprolisView full Kyprolis profile
TecvayliView full Tecvayli profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.